To clarify this discrepancy, rapamycin was used to treat T-ALL cells and the data showed that both SESN3 overexpression and rapamycin treatment resulted in the decreased ATG4B expression at posttranscriptional level but not ATG5. Here, ATG4B is linked to acute lymphoblastic leukemia.